Table 3.
Cox proportional hazard regression analysis for cyclophosphamide, vincristine, doxorubicin, and prednisolone (CHOP) and rituximab (R)‐CHOP
| Clinical outcome | CHOP (n = 451) | R‐CHOP (n = 279) | ||
|---|---|---|---|---|
| HR (95% CI) | P‐value | HR (95% Cl) | P‐value | |
| OS Bcl‐2 (+ vs –) | 1.331 (1.000–1.773) | 0.049 | 1.160 (0.653–2.062) | 0.612 |
| Bcl‐6 (– vs +) | 1.243 (0.896–1.724) | 0.194 | 2.173 (1.116–4.230) | 0.022 |
| Age (per year) | 1.028 (1.014–1.042) | <0.001 | 1.032 (1.009–1.055) | 0.006 |
| Clinical stage (III–IV vs I–II) | 1.940 (1.438–2.617) | <0.001 | 1.986 (1.031–3.825) | 0.040 |
| ECOG PS (II–IV vs 0–I) | 1.400 (0.998–1.964) | 0.050 | 2.526 (1.366–4.670) | 0.003 |
| Lactate dehydrogenase (>normal) | 1.817 (1.350–2.444) | <0.001 | 2.416 (1.247–4.679) | 0.009 |
| No. extranodal sites (≥2 vs 0–1) | 1.233 (0.862–1.763) | 0.251 | 0.976 (0.505–1.885) | 0.942 |
Adjusted for age, cell origin, and center effect. CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio.